Antidepressants for OPRA: SSRIs, Serotonin Toxicity and MCQs

Onset, duration and the counselling that goes with them

Antidepressants do not work immediately. Some improvement in sleep, appetite and energy may appear within the first one to two weeks, but a meaningful effect on mood generally takes around two to four weeks, and the full response can take six weeks or longer. This gap is the single most important counselling point at first dispensing, because a patient who expects a rapid effect is a patient who stops early.

Duration matters just as much. Treatment continues for a substantial period after symptoms resolve — typically at least six to twelve months for a first episode — because stopping at the point of feeling well carries a high relapse risk. Patients often interpret feeling better as evidence the medicine is no longer needed, which is precisely backwards.

Serotonin toxicity — the features and the triggers

Serotonin toxicity (serotonin syndrome) results from excessive serotonergic activity, most often from combining two or more serotonergic agents rather than from one drug alone. It presents as a triad: neuromuscular excitation, autonomic instability, and altered mental state.

The neuromuscular features are the most discriminating — clonus (particularly inducible or spontaneous clonus), hyperreflexia, tremor and rigidity, classically more pronounced in the lower limbs. Autonomic features include fever, tachycardia, sweating, diarrhoea and dilated pupils. Mental state changes range from agitation and anxiety to confusion. Onset is typically rapid, within hours of the precipitating dose or combination, which helps distinguish it from conditions with a slower evolution.

• Highest-risk combinations involve an MAOI with any other serotonergic agent — this is the combination most likely to produce severe toxicity.
• SSRI or SNRI combined with tramadol is a common and heavily tested community-practice trigger.
• Linezolid is a frequently missed culprit — it has MAOI activity despite being dispensed as an antibiotic.
• St John's wort is serotonergic and is often taken without being disclosed as a medicine, making it a classic exam detail.
• Other contributors include triptans, certain opioids such as pethidine and fentanyl, and combining two antidepressants during a switch.

Discontinuation syndrome

Stopping an antidepressant abruptly — or missing several doses — can produce a withdrawal-type reaction: flu-like symptoms, insomnia and vivid dreams, nausea, imbalance and dizziness, sensory disturbances often described as electric-shock or "zap" sensations, and irritability or agitation.

Risk is highest with agents that have a short half-life and no active metabolite, notably paroxetine and venlafaxine. Fluoxetine, with its long half-life and long-acting metabolite, effectively tapers itself and is much less associated with discontinuation symptoms. The practical implication is that antidepressants are tapered rather than stopped abruptly, with the taper pace guided by the specific agent.

Distinguishing discontinuation from relapse is a genuine exam point: discontinuation symptoms begin within days of stopping, are often physical rather than purely mood-based, and resolve quickly if the medicine is restarted, whereas relapse of depression typically evolves over weeks and reproduces the original mood symptoms.

Switching and washout

Switching between serotonergic antidepressants risks overlapping their effects. The washout required depends chiefly on the half-life of the drug being stopped: most SSRIs need a substantial gap before an MAOI is started, and fluoxetine needs considerably longer than the others because its active metabolite persists for weeks after the last dose.

Going the other direction — from an MAOI to another serotonergic antidepressant — also requires a washout, because the enzyme inhibition outlasts the drug itself.

• Fluoxetine needs the longest washout of any SSRI — it is the standing exception, because of its long-acting active metabolite.
• Any switch involving an MAOI requires a specific washout in both directions, never a direct changeover.
• Never overlap two serotonergic antidepressants casually — the overlap itself is a serotonin toxicity risk, not just an administrative untidiness.
• Check the specific interval in a current reference rather than recalling it: the figure varies by agent, and it is the kind of detail that changes.

The high-yield summary

If you revise nothing else from this article, revise this. Each line is a pattern that recurs across OPRA stems rather than an isolated fact.

• Onset — meaningful mood effect takes about 2–4 weeks, full response longer; counsel this at first dispensing.
• Duration — continue well beyond symptom resolution (typically at least 6–12 months for a first episode), then taper.
• Serotonin toxicity — clonus is the giveaway; onset within hours; tramadol, linezolid, St John's wort and MAOIs are the triggers to scan for.
• Discontinuation — days after stopping, electric-shock sensations; worst with paroxetine and venlafaxine, least with fluoxetine.
• Bleeding — SSRI plus NSAID or anticoagulant raises GI bleeding risk.
• Sodium — an older patient who becomes confused or falls in the first weeks needs a sodium check.
• QT — citalopram and escitalopram have dose caps that are lower in older patients.

Practise this topic

Recognising which of four plausible-sounding options is the actual safety intervention is the skill these questions test. Practise more Therapeutics and CNS OPRA questions with ClinicalStem's OPRA question bank.

Bleeding risk with SSRIs

SSRIs reduce platelet serotonin uptake and therefore impair platelet aggregation, producing a modest but real increase in bleeding risk — most relevantly upper gastrointestinal bleeding. On its own this is usually of limited significance; combined with an NSAID, an anticoagulant or an antiplatelet, the risk rises meaningfully.

The practical consequence in community practice is that a request for regular over-the-counter ibuprofen from a patient taking an SSRI warrants a conversation rather than a straightforward sale, and that a patient on an SSRI plus an NSAID may be a candidate for gastroprotection. This is a common OPRA stem shape precisely because the interaction is invisible unless you look for it.

Hyponatraemia, particularly in older patients

SSRIs and SNRIs can cause hyponatraemia through a syndrome of inappropriate antidiuretic hormone secretion, with older patients, women, low body weight and concurrent diuretic use all increasing the risk. It typically appears within the first weeks of starting or increasing a dose.

The presentation is easy to attribute to something else — lethargy, confusion, headache, unsteadiness or falls in an older patient are just as readily blamed on age, on the depression itself, or on other medicines. An older patient who becomes confused shortly after an antidepressant is started should prompt a sodium check, and OPRA rewards candidates who reach for that rather than for a dose increase.

Adverse effects that drive non-adherence

• Sexual dysfunction is common with SSRIs, frequently under-reported, and a leading reason patients quietly stop — raising it proactively is a genuine pharmacist intervention rather than an optional extra.
• Nausea and gastrointestinal upset are common early and often settle within the first week or two, which is worth saying at the point of first dispensing.
• Initial anxiety, restlessness or agitation can occur in the first days and is a recognised reason for close early follow-up rather than an automatic reason to stop.
• Younger patients, particularly those under 25, require closer monitoring early in treatment because of an increased risk of suicidal thinking and behaviour in that group.
• Venlafaxine can raise blood pressure in a dose-related way, making blood pressure monitoring relevant at higher doses.
• Mirtazapine is notably sedating and associated with increased appetite and weight gain — the sedation is often more pronounced at lower doses, which is counterintuitive and therefore tested.

QT prolongation with citalopram and escitalopram

Citalopram and escitalopram carry dose-dependent QT prolongation, which is why maximum doses are specified and are lower in older patients and in those with hepatic impairment or relevant risk factors. The risk compounds with other QT-prolonging medicines and with electrolyte disturbance — itself a possible consequence of SSRI-induced hyponatraemia.

A prescription exceeding the recommended maximum for an older patient is a clear pharmacist intervention, and it is a favourite exam construction because the dose looks unremarkable until you notice the patient's age.

How long do antidepressants take to work?

Sleep, appetite and energy may improve within the first week or two, but a meaningful effect on mood generally takes around two to four weeks, with full benefit sometimes taking six weeks or more. Counselling patients about this delay at first dispensing is one of the most effective ways to prevent early discontinuation.

What are the key signs of serotonin toxicity?

A triad of neuromuscular excitation (clonus, hyperreflexia, tremor, rigidity — often most marked in the legs), autonomic instability (fever, tachycardia, sweating, dilated pupils, diarrhoea) and altered mental state (agitation, confusion). Onset is typically within hours of the precipitating drug or combination, and clonus is the most discriminating feature.

Is discontinuation syndrome the same as addiction?

No. Discontinuation symptoms reflect the body adjusting to the sudden absence of a medicine and are not accompanied by craving or compulsive use. They are prevented by tapering rather than by abrupt cessation, and are most likely with short half-life agents such as paroxetine and venlafaxine.

Why do citalopram and escitalopram have lower maximum doses in older patients?

Both prolong the QT interval in a dose-dependent way, and that risk is greater in older patients, so age-adjusted maximum doses apply. A prescription at the standard adult maximum for an older patient is a common and legitimate pharmacist intervention.

Can a patient stop their antidepressant once they feel better?

Not immediately. Treatment usually continues for at least six to twelve months after symptoms resolve for a first episode, because stopping at the point of feeling well carries a high risk of relapse. Any cessation should be a planned taper rather than an abrupt stop.